6-氯-2-萘磺酰氯 | 102153-63-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 6-氯-2-萘磺酰氯
• 英文名称: 6-chloronaphth-2-ylsulfonyl chloride
• 英文别名: 6-chloro-2-naphthalenesulfonyl chloride；6-Chloro-2-Naphthylsulfonyl Chloride；6-chloronaphthalene-2-sulfonyl chloride
• CAS: 102153-63-9
• 化学式: C₁₀H₆Cl₂O₂S
• mdl: MFCD04037080
• 分子量: 261.128
• InChiKey: IYFIYGSJZIICOZ-UHFFFAOYSA-N

物化性质

• 熔点：
  108 °C
• 沸点：
  402.9±20.0 °C(Predicted)
• 密度：
  1.516±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2904909090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P260,P280,P303+P361+P353,P301+P330+P331,P304+P340+P310,P305+P351+P338+P310
• 危险品运输编号：
  3261
• 危险性描述：
  H314
• 储存条件：
  | 温度范围 | 保存条件 | | --- | --- | | 2-8°C | 惰性气体 |

制备方法与用途

化学性质：这是一种灰色至褐黄色的晶体粉末，熔点为108-110℃。

反应信息

• 作为反应物：
  描述：

  6-氯-2-萘磺酰氯 在 N-甲基吗啉 、 盐酸 、 1-羟基苯并三唑一水物 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 1.55h， 生成 [4-(6-Chloro-naphthalene-2-sulfonyl)-piperazin-1-yl]-(5-methyl-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridin-2-yl)-methanone
  参考文献：
  名称：

  Synthesis and Conformational Analysis of a Non-Amidine Factor Xa Inhibitor That Incorporates 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 Binding Element

  摘要：

  Our exploratory study was based on the concept that a non-amidine factor Xa (fXa) inhibitor is suitable for an orally available anticoagulant. We synthesized and evaluated a series of N-(6-chloronaphthalen-2-yl)sulfonylpiperazine derivatives incorporating various fused-bicyclic rings containing an aliphatic amine expected to be S4 binding element. Among this series, 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine type 61 displayed orally potent anti-fXa activity and evident prolongation of prothrombin time (PT) with the moderate bioavailability in rats. The X-ray crystal analysis afforded an obvious binding mode that 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine and 6-chloronaphthalene respectively bound to S4 and S1 subsites. In this X-ray study, we discovered a novel intramolecular S-O close contact. Ab initio energy calculations of model compounds deduced that conformers with the most close S-O proximity were most stable. The Mulliken population analysis proposed that this energy profile was caused by both of electrostatic S-O affinity and N-O repulsion. The results of these calculations and X-ray analysis suggested a possibility that the restricted conformation effected the affinity to S4 subsite of fXa.

  DOI：

  10.1021/jm049884d
• 作为产物：
  描述：

  2-氯萘 在 氯化亚砜 、 硫酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 6-氯-2-萘磺酰氯
  参考文献：
  名称：

  Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine derivatives

  摘要：

  In our investigation of factor Xa inhibitors, a series of 1-(6-chloronaphthalen-2-yl)sulfonyl-4-(4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carbonyl)piperazines 3a-i were synthesized. In vitro inhibitory activities of the compounds against factor Xa and coagulation are summarized. Among the compounds, 3c and 3d, possessing a carbamoyl or N-methylcarbamoyl moiety, showed potent inhibitory activities when administered orally to rats. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.036
• 作为试剂：
  描述：

  ethyl 2-[(2,2-diethoxyethyl)amino]acetate 在 6-氯-2-萘磺酰氯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以750 mg的产率得到N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-(2,2-diethoxyethyl)glycine ethyl ester
  参考文献：
  名称：

  TRICYCLIC COMPOUNDS HAVING SPIRO UNION

  摘要：

  公开号：

  EP1191028B1

文献信息

• Sulfonamide derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06359134B1

  公开（公告）日：2002-03-19

  The present invention provides compounds which specifically inhibit FXa, which are effective when orally administered and which are useful as a safe medicine for the prevention or treatment of diseases caused by thrombus or infarction. Compounds of this invention are piperazinones of the formula: wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; the ring A is an optionally substituted divalent nitrogen-containing heterocyclic group, in addition to being substituted by the group of the formula: and the group of the formula: Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent heterocyclic group; X is a direct bond or an optionally substituted alkylene chain; Z is (1) an amino group substituted with an optionally substituted hydrocarbon group, (2) an optionally substituted imino group or (3) an optionally substituted nitrogen-containing heterocyclic group; provided that when X is a direct bond and Z is an optionally substituted 6-membered nitrogen-containing aromatic heterocyclic group, Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent unsaturated heterocyclic group; or a salt thereof.

  本发明提供了一种化合物，该化合物特异性地抑制FXa，口服给药有效，并且用作预防或治疗由血栓或梗死引起的疾病的药物是安全的。本发明的化合物是哌嗪酮的公式： 其中R1是可选地取代的烃基或可选地取代的杂环基；环A是除了被公式：的基团取代的之外的可选地取代的二价含氮杂环基： 和公式的基团： Y是可选地取代的二价烃基或可选地取代的二价杂环基；X是直接键或可选地取代的亚烷基链；Z是（1）与可选地取代的烃基取代的氨基，（2）可选地取代的亚氨基或（3）可选地取代的含氮杂环基；当X是直接键并且Z是可选地取代的6-成员含氮芳香杂环基时，Y是可选地取代的二价烃基或可选地取代的二价不饱和杂环基；或其盐。
• [EN] NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL<br/>[FR] NOUVEL OCTAHYDRO-CYCLOBUTA [1,2-C; 3,4-C'] DIPYRROL-2-YL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015078803A1

  公开（公告）日：2015-06-04

  The invention provides novel compounds having the general formula (I) wherein R1, Y and R2 are as described herein, compositions including the compounds and methods of using the compounds.

  这项发明提供了具有一般式（I）的新化合物，其中R1、Y和R2如本文所述，包括这些化合物的组合物和使用这些化合物的方法。
• Aminoheterocyclic derivatives as antithrombotic or anticoagulant
  申请人：Zeneca Limited

  公开号：US05965559A1

  公开（公告）日：1999-10-12

  The invention concerns compounds of formula (I), wherein each of G.sup.1, G.sup.2 and G.sup.6 is CH or n; m is 1 or 2; R.sup.1 includes hydrogen, halogeno and (1-4C)alkyl; M.sup.1 is a group of formula: NR.sup.2 -L.sup.1 -T.sup.1 R.sup.3, in which R.sup.2 and R.sup.3 together form a (1-4C)alkylene group, L.sup.1 includes (1-4C)alkylene, and T.sup.1 is CH or N; A may be a direct link; M.sup.2 is a group of the formula: (T.sup.2 R.sup.4).sub.r -L.sup.2 T.sup.3 R.sup.5 in which R is 0 or 1, each of T.sup.2 and T.sup.3 is CH or N, each of R.sup.4 and R.sup.5 is hydrogen or (1-4C)alkyl, or R.sup.4 and R.sup.5 together form a (1-4C)alkylene group, and L.sup.2 includes (1-4C)alkylene; M.sup.3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocycle moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.

  该发明涉及式(I)的化合物，其中G.sup.1、G.sup.2和G.sup.6中的每一个是CH或n；m为1或2；R.sup.1包括氢、卤代和(1-4C)烷基；M.sup.1是式的一个基团：NR.sup.2 -L.sup.1 -T.sup.1 R.sup.3，在其中R.sup.2和R.sup.3共同形成一个(1-4C)烷基基团，L.sup.1包括(1-4C)烷基，T.sup.1为CH或N；A可以是直接连接；M.sup.2是式的一个基团：(T.sup.2 R.sup.4).sub.r -L.sup.2 T.sup.3 R.sup.5，在其中R为0或1，T.sup.2和T.sup.3中的每一个是CH或N，R.sup.4和R.sup.5中的每一个是氢或(1-4C)烷基，或R.sup.4和R.sup.5共同形成一个(1-4C)烷基基团，L.sup.2包括(1-4C)烷基；M.sup.3可以是到X的直接连接；X包括磺酰基；Q包括萘基和杂环基；或其药学上可接受的盐；它们的制备方法，含有它们的药物组合物以及它们作为抗血栓或抗凝血剂的用途。
• [EN] LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS<br/>[FR] DIAMINES CYCLIQUES CONTENANT DU LACTAME ET LEURS DERIVES UTILISES EN TANT QU'INHIBITEURS DU FACTEUR XA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2004082687A1

  公开（公告）日：2004-09-30

  The present application describes lactam-containing cyclic diamines and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein M is a non-aromatic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trysin-like serine proteases, specifically factor Xa.

  本申请描述了含有内酰胺的环状二胺及其衍生物的化合物，化学式如下：或其药用可接受的盐形式，其中M是非芳香族碳环或杂环。本发明的化合物可用作特异性抑制try sin-like丝氨酸蛋白酶，特别是Xa因子。
• Sulfone derivatives, process for their production and use thereof
  申请人：——

  公开号：US20030187023A1

  公开（公告）日：2003-10-02

  A compound represented by the formula: 1 wherein R is a cyclic hydrocarbon group, or the like; W is a bond, or the like; X is a divalent hydrocarbon group, or the like; Y and Z are each independently —N(R 6 )— or the like; ring A is a nitrogen-containing heterocyclic ring, or the like; R5 and R6 are independently hydrogen atom, a hydrocarbon group, or the like; Z′ is imidoyl group, or the like; a is 0, 1 or 2; and b is 0 or 1, or a salt thereof.

  一个由以下式表示的化合物： 其中R是一个环烃基团，或类似物；W是一个键，或类似物；X是一个二价碳氢基团，或类似物；Y和Z分别独立地为—N(R6)—或类似物；环A是一个含氮杂环环，或类似物；R5和R6独立地为氢原子、一个碳氢基团，或类似物；Z′是亚胺基团，或类似物；a为0、1或2；b为0或1，或其盐。